# Danaher (DHR) Forecast Calculator

Interactive five-year financial forecast and DCF for Danaher. Adjust revenue growth, margins, capex, and WACC to update revenue, free cash flow, and enterprise value.

- Canonical: https://finamodel.com/companies/danaher/forecast
- Industry: Healthcare
- Forecast start year: 2026

## Historical data

| Year | Revenue | Free cash flow | EBITDA | Net income |
|---:|---:|---:|---:|---:|
| 2021 | 17911000000 | 3316000000 | 4458000000 | 3008000000 |
| 2022 | 22284000000 | 5417000000 | 6006000000 | 3646000000 |
| 2023 | 24802000000 | 7118000000 | 8439000000 | 6433000000 |
| 2024 | 26643000000 | 7401000000 | 8234000000 | 7209000000 |
| 2025 | 23890000000 | 5781000000 | 5877000000 | 4764000000 |

## Frequently asked questions

### What does Danaher Corporation (DHR) do and what are its main business segments?

Danaher is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and commercial products and services. Its primary business segments include Biotechnology, Life Sciences, and Diagnostics, with Diagnostics contributing approximately 40% of its revenue. The company operates a "razor/razorblade" model, generating highly recurring revenue from consumables.

### How does Danaher generate revenue, and what is its core business model?

Danaher primarily generates revenue through a "razor/razorblade" business model, where the sale of instruments drives recurring sales of high-margin consumables. Consumables represent a significant portion of segment revenues, ranging from 67% to 89%. This model is underpinned by the proprietary Danaher Business System (DBS), which focuses on continuous operational improvement.

### What are the key financial assumptions for Danaher's revenue growth and operating expenses in its financial model?

The financial model for Danaher assumes a revenue growth rate of approximately 7.47%. Key operating expense assumptions include COGS at about 41.47% of revenue, R&D at 6.08% of revenue, and SGA at 29.41% of revenue. These percentages are crucial for projecting the company's future profitability and cash flows.

### What is Danaher's capital expenditure strategy and working capital profile?

Danaher's capital expenditure is projected at approximately 4.42% of revenue, with about 60% allocated to growth capex, specifically for expanding bioprocessing manufacturing capacity. The company maintains a slightly positive net working capital profile, typically low single digits as a percentage of revenue. The Danaher Business System ensures working capital grows much slower than revenue, often acting as a source of cash.

### What is the primary purpose of the Danaher (DHR) financial model and what can it help assess?

The Danaher financial model serves as a comprehensive equity valuation and scenario planning tool. It enables analysts to assess the intrinsic value of Danaher's post-spin-off life sciences and diagnostics portfolio. Additionally, the model helps evaluate the impact of bioprocessing market normalization on the company's financial performance.

### Is an Excel financial model available for Danaher (DHR) and what is its forecast period?

Yes, an Excel financial model for Danaher (DHR) is available for download. This model provides a detailed forecast horizon covering fiscal years 2026 through 2030. It allows for in-depth analysis of the company's future financial performance and valuation.